ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. plans to hold a Capital Markets Day in London on September 8, 2026, beginning at 10:00 a.m. ET (3:00 p.m. BST). Leadership intends to provide a comprehensive update on strategic direction and commercial momentum, including nuclear medicine, electronic gases, nuclear fuels, and the long-term market opportunity in each area.
The event will run from 10:00 a.m. to 12:30 p.m. ET with a formal Q&A; in-person attendance is invitation-only, but the public can join via live webcast, with materials and a replay available on the company’s investor relations website. The disclosure is furnished under Regulation FD, not filed.
The communication also describes a proposed merger and related transactions involving ENDRA Life Sciences, Renergen, and Noble Africa, stating that ENDRA intends to file a Form S-4 with a proxy statement/prospectus and urging ENDRA stockholders to review those materials when available. Extensive cautionary language outlines that forward-looking statements, including expectations about the proposed transactions and ASP Isotopes’ projects and regulatory approvals, are subject to numerous risks and uncertainties.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy LLC (QLE), has entered into a research agreement with the Texas A&M Engineering Experiment Station (TEES) to advance and de‑risk the commercial production of high-purity uranium hexafluoride (UF6), a key feedstock in the nuclear fuel enrichment supply chain.
The collaboration will generate fundamental physicochemical data on converting yellowcake uranium (U3O8) into UF6, supporting efforts to improve production technology, reduce costs, and enhance scalability for domestic uranium conversion. QLE is a development-stage nuclear fuels company focused on uranium conversion, U‑235 enrichment (including HALEU, LEU+ and LEU), lithium isotope separation, and radioactive waste treatment, using proprietary Aerodynamic Separation Process and Quantum Enrichment technologies. ASP Isotopes develops isotope enrichment platforms and operates enrichment facilities in Pretoria, South Africa. The announcement includes extensive cautionary language regarding forward-looking statements and related risks.
ASP Isotopes Inc., a Delaware corporation based in Dallas, filed a notice of an exempt securities offering under Regulation D, Rule 506(b). The offering covers equity securities reflecting the exchange of $109,181,606 of aggregate principal plus accrued unpaid interest on convertible promissory notes previously issued by a subsidiary into common stock of ASP Isotopes. The total amount sold is $109,181,606 with $0 remaining to be sold. The issuer reports annual revenues of over $100,000,000 and indicates no finder’s fees were paid.
ASP Isotopes Inc. has registered the resale by certain selling stockholders of 23,160,682 shares of common stock under an automatic shelf registration. These shares were issued in exchange for $109,181,606 of 8% Convertible Promissory Notes due November 19, 2030 of subsidiary Quantum Leap Energy LLC, plus accrued interest, under Securities Exchange Agreements dated July 15, 2026. The company is not selling shares and will not receive any proceeds from these resales, although it will bear registration expenses.
After issuing these shares, common stock outstanding was 153,309,380 as of July 16, 2026, within an authorized capital of 500,000,000 common and 10,000,000 preferred shares. The prospectus also highlights the January 2026 acquisition of Renergen Limited, for which 14,270,000 consideration shares were issued; Renergen operates the Virginia Gas Project producing liquid helium and LNG in South Africa.
ASP Isotopes Inc. plans to exchange a portion of the convertible promissory notes of its wholly owned subsidiary, Quantum Leap Energy (QLE), for common equity in ASP Isotopes. Holders of approximately $109.2 million in aggregate principal amount of QLE convertible notes, plus accrued interest, have agreed to receive an aggregate of approximately 23.2 million shares of ASP Isotopes common stock, representing approximately 17.8% of ASP Isotopes’ common stock outstanding.
At closing, QLE’s outstanding convertible notes are expected to be reduced by approximately 50%, from $219.8 million to $110.7 million in aggregate principal amount, simplifying QLE’s capital structure as it pursues a separate public listing on a U.S. national securities exchange. The exchange transactions are also expected to support ASP Isotopes’ position for a potential future distribution of its QLE common equity to ASP Isotopes stockholders, and are expected to close on July 16, 2026, subject to customary conditions.
ASP Isotopes Inc.’s Chief Financial Officer, Heather Kiessling, reported an open-market sale of 23,124 shares of common stock at a weighted average price of $6.28 per share. According to the footnotes, these were “sell to cover” trades under a Rule 10b5-1 trading plan to satisfy tax withholding from quarterly vesting of a restricted stock award.
After the transaction, she directly holds 1,526,252 shares of ASP Isotopes common stock, indicating that the sale represents a small portion of her overall equity position and is tied to a pre-arranged, tax-related mechanism rather than a discretionary reduction in holdings.
ASP Isotopes Inc. executive Donald George Ainscow, EVP, General Counsel and Secretary, reported an open-market sale of 100,000 shares of Common Stock. The weighted average sale price was $6.14 per share, with individual trades occurring between $6.11 and $6.17 per share.
Following this transaction, Ainscow directly holds 800,000 shares of ASP Isotopes Inc. common stock. The filing notes that detailed trade-by-trade pricing within the reported range is available upon request.
ASP Isotopes Inc. director Todd Wider sold 100,000 shares of Common Stock in open-market transactions. The Form 4 shows two sales of 50,000 shares each, at reported prices of $6.12 and $6.25 per share, executed as multiple trades within stated price ranges.
Footnotes explain that each reported price is a weighted average, with actual trade prices between $6.21 and $6.31 for one block and between $6.10 and $6.25 for the other. Overall, the filing reflects a net sale of 100,000 shares by the director.
ASP Isotopes Inc. director Michael Gorley sold 30,000 shares of Common Stock in an open-market transaction at a weighted average price of approximately $6.27 per share. After this sale, he directly holds 87,908 shares, indicating he retains a significant ongoing equity position.
According to the disclosure, the shares were sold in multiple trades at prices ranging from $6.10 to $6.63 per share, with the weighted average reported. The filing notes that full trade-by-trade pricing details are available upon request from the company, any stockholder, or the SEC staff.